Bayer's $7 Billion Roundup Settlement Faces Investor Skepticism, Shares Plummet

• Bayer's proposed $7.25 billion class-action settlement for Roundup cancer claims draws investor doubt, despite initial optimism.
• Shares dropped 12% after a 7.4% rally, marking the steepest slide in over a year.
• The settlement is contingent on court approval and high participation, with Bayer able to terminate if targets aren't met.
• The deal is costly, requiring an $8 billion bridge loan and potentially negative free cash flow in 2026.
• CEO Bill Anderson aims to resolve litigation by 2026, but past attempts by predecessors failed due to judicial rejection.